ABCG2 p.Asn596Ala
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 15835752
[PubMed]
Takada T et al: "Characterization of polarized expression of point- or deletion-mutated human BCRP/ABCG2 in LLC-PK1 cells."
No.
Sentence
Comment
36
Using the site-directed mutagenesis technique, several mutants of BCRP (N418A, N596A, N418A&N596A BCRP and C592A, C603A&C608A, C592A&C603A&C608A BCRP) were constructed on pcDNA3.1(+) vector.
X
ABCG2 p.Asn596Ala 15835752:36:79
status: VERIFIED57 Western blot analysis revealed that the modification was on the latter asparagine (Fig. 3B); the N418A mutant was N-glycosylated, whereas the N596A and N418A&N596A mutants did not exhibit any alteration in molecular weight following PNGase F treatment.
X
ABCG2 p.Asn596Ala 15835752:57:142
status: VERIFIED
PMID: 15875186
[PubMed]
Mohrmann K et al: "Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2)."
No.
Sentence
Comment
6
We found that only BCRP-N596A and a mutant with all three asparagines mutated (triple mutant) were not glycosylated anymore, indicating that only asparagine 596 is normally glycosylated.
X
ABCG2 p.Asn596Ala 15875186:6:24
status: VERIFIED45 BCRP-N418A, BCRP-N557A and BCRP-N596A were made using pcDNA3/BCRP wild type (GenBank accession number AY017168; generously provided by Susan Bates) as template.
X
ABCG2 p.Asn596Ala 15875186:45:32
status: VERIFIED46 BCRP-N418A/ N557A was made using overlap extension PCR with pGEM-T Easy/BCRP-N418A as template and BCRP-N418A/N557A/N596A was made with pGEM-T Easy/ BCRP-N418A/N557A as template again using overlap extension PCR.
X
ABCG2 p.Asn596Ala 15875186:46:116
status: VERIFIED110 A protein containing all three mutations [triple (T) mutant] showed the same result as the BCRP-N596A mutant.
X
ABCG2 p.Asn596Ala 15875186:110:96
status: VERIFIED131 The non-glycosylated BCRP-N596A mutant, however, showed a normal plasma membrane staining in both CHO9 and MDCKII cells, indicating that N-glycosylation of BCRP is not important for its plasma membrane targeting.
X
ABCG2 p.Asn596Ala 15875186:131:26
status: VERIFIED155 Fig. 3 BCRP-N596A is not glycosylated.
X
ABCG2 p.Asn596Ala 15875186:155:12
status: VERIFIED156 Empty vector pcDNA3 or pcDNA3 with BCRP or mutant BCRP, BCRP-N418A, BCRP-N557A and BCRP-N596A, was transiently transfected into CHO9 cells or MDCKII cells using FuGENE6.
X
ABCG2 p.Asn596Ala 15875186:156:88
status: VERIFIED186 Annu Rev Cell Dev Biol 16:113-143 Fig. 4 Wild-type BCRP, BCRP-N418A and BCRP-N596A are localized at the plasma membrane.
X
ABCG2 p.Asn596Ala 15875186:186:77
status: VERIFIED188 Empty vector pcDNA3 or pcDNA3 with BCRP or mutant BCRP, BCRP-N418A, BCRP-N557A and BCRP-N596A, was transiently transfected into CHO9 cells or MDCKII cells using FuGENE6.
X
ABCG2 p.Asn596Ala 15875186:188:88
status: VERIFIED
PMID: 24130050
[PubMed]
Hou H et al: "Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma."
No.
Sentence
Comment
190
A previous report showed that NLG is not essential for routing ABCG2 to the plasma membrane because the N596A mutation had little effect on ABCG2 subcellular localization (28).
X
ABCG2 p.Asn596Ala 24130050:190:104
status: NEW